• Ilyang Pharmaceutical was designated an “unfaithful disclosure” company on Oct. 8, 2026 for disclosure non-compliance.
• Sanctions include 7 penalty points, taking its cumulative total to 7, and a KRW 70 million regulatory fine.
• The case cites delayed disclosure tied to a supply contract correction and delayed disclosure of a contract termination.
• Reaching 10 penalty points within one year could trigger a substantive listing eligibility review under Korea Exchange rules.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ilyang Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007800786), on October 07, 2026, and is solely responsible for the information contained therein.